



December 12, 2018

Dear Colleague:

NCQA released a stop-work notification on November 28 for all six Electronic Clinical Data Systems (ECDS) measures and their corresponding digital measure packages for HEDIS^{®1} 2019 Volume 2. NCQA reviewed the measure packages. This memo outlines the errors identified during the review and is the HEDIS 2019 *Volume 2: ECDS Technical Update*. With this release, NCQA freezes the ECDS technical specifications for Volume 2.

We apologize for any inconvenience this has caused you.

This memo contains the following information:

- A summary of the digital measure packages logic updates for HEDIS 2019.
- Corrections, policy changes and clarifications to HEDIS 2019 *Volume 2: ECDS Technical Specifications*.

The following measures are affected by this memo:

- Depression Screening and Follow-Up for Adolescents and Adults (DFS).
- Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (DMS).
- Depression Remission or Response for Adolescents and Adults (DRR).
- Unhealthy Alcohol Use Screening and Follow-Up (ASF).
- Adult Immunization Status (AIS).
- Prenatal Immunization Status (PRS).

This memo does not contain the full changes to the *HEDIS 2019 Digital Measure Packages*. The digital measure packages will be available on December 12, and must be downloaded from the NCQA Download Center (<https://downloads.ncqa.org/customer/Login.aspx>) to obtain the updated versions for all six ECDS measures.

The corrections addressed in this memo do not affect the traditional non-ECDS HEDIS measures, which were frozen with the release of the HEDIS 2019 *Volume 2: Technical Update* on October 1.

Review all items in the following tables and incorporate them into your implementation processes. HEDIS Compliance Auditors will consider these documents to be part of the specifications. If you have questions about information included in the *ECDS Technical Update* or about other measure specifications, submit them to the Policy Clarification Support (PCS) system at <http://my.ncqa.org>.

Sincerely,

Cindy Ottone, MHA
Director, Policy-Measures

Enclosure

¹HEDIS[®] is a registered trademark of the National Committee for Quality Assurance (NCQA).

HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA). The HEDIS measures and specifications were developed by and are owned by NCQA. NCQA holds a copyright in the HEDIS measures and specifications and may rescind or alter these measures and specifications at any time. Users of the HEDIS measures and specifications shall not have the right to alter, enhance or otherwise modify the HEDIS measures and specifications, and shall not disassemble, recompile or reverse engineer the HEDIS measures and specifications. Anyone desiring to use or reproduce the materials, subject to licensed user restrictions, without modifications for an internal, non-commercial purpose may do so without obtaining any approval from NCQA. Use of the *Rules for Allowable Adjustments of HEDIS* to make permitted adjustments of the materials does not constitute a modification. All other uses, including a commercial use, or any external reproduction, distribution and publication must be approved by NCQA and are subject to a license at the discretion of NCQA.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording or any information storage and retrieval system, without the written permission of NCQA.

HEDIS measures and specifications are not clinical guidelines, do not establish a standard of medical care and have not been tested for all potential applications. The measures and specifications are provided “as is” without warranty of any kind. NCQA makes no representations, warranties or endorsements about the quality of any product, test or protocol identified as numerator compliant or otherwise identified as meeting the requirements of a HEDIS measure or specification. NCQA also makes no representations, warranties or endorsements about the quality of any organization or clinician who uses or reports performance measures. NCQA has no liability to anyone who relies on HEDIS measures and specifications or data reflective of performance under such measures and specifications.

Calculated measure results, based on unadjusted HEDIS specifications, may not be termed “Health Plan HEDIS rates” until they are audited and designated reportable by an NCQA-Certified Auditor. Such results should be referred to as “Unaudited Health Plan HEDIS Rates.” Additionally, calculated measure results, based on adjusted HEDIS specifications, may be called only “Uncertified, Unaudited HEDIS rates.” In this publication, “Health Plan HEDIS rate” refers to and assumes a result from unadjusted HEDIS specification that has been audited by an NCQA-Certified HEDIS Auditor.

Limited proprietary coding is contained in the measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. NCQA disclaims all liability for use or accuracy of any coding contained in the specifications.

The American Medical Association holds a copyright to the CPT® codes contained in the measures specifications.

The American Hospital Association holds a copyright to the Uniform Bill Codes (UB) contained in the measure specifications. The UB Codes in the HEDIS specifications are included with the permission of the AHA. The UB Codes contained in the HEDIS specifications may be used by health plans and other health care delivery organizations for the purpose of calculating and reporting HEDIS measure results or using HEDIS measure results for their internal quality improvement purposes. All other uses of the UB Codes require a license from the AHA. Anyone desiring to use the UB Codes in a commercial Product(s) to generate HEDIS results, or for any other commercial use, must obtain a commercial use license directly from the AHA. To inquire about licensing, contact ub04@healthforum.com.

Some measure specifications contain coding from LOINC® (<http://loinc.org>). The LOINC table, LOINC codes, LOINC panels and form file, LOINC linguistic variants file, LOINC/RSNA Radiology Playbook, and LOINC/IEEE Medical Device Code Mapping Table are copyright © 1995–2018, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee and is available at no cost under the license at <http://loinc.org/terms-of-use>.

“SNOMED” and “SNOMED CT” are registered trademarks of the International Health Terminology Standards Development Organisation (IHTSDO).

“HL7” is the registered trademark of Health Level Seven International.

© 2018 by the National Committee for Quality Assurance, all rights reserved.

NCQA Customer Support: 888-275-7585

NCQA Policy Clarification Support at: <http://my.ncqa.org>

Summary of Digital Measure Package Logic Updates

This document contains a summary of the corrections to the digital measure packages for the HEDIS 2019 Volume 2 ECDS measures. NCQA has identified the appropriate measure and logic definition for each item.

Measure	Update
Depression Screening and Follow-Up for Adolescents and Adults (DSF)	<ul style="list-style-type: none"> • Updated the logic definition for “Initial Population” • Updated the logic definition for “Denominator Exclusions” • Updated the logic definition for “Adult Depression Screen with Positive Result” • Updated the logic definition for “Positive Adult Screen” • Updated the logic definition for “Positive Adolescent Screen”
Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (DMS)	<ul style="list-style-type: none"> • Updated the logic definition for “Initial Population” • Updated the logic definition for “Denominator Exclusions” • Updated the logic definition for “Assessment Period 1” • Updated the logic definition for “Assessment Period 2” • Updated the logic definition for “Assessment Period 3” • Updated the logic definition for “Depression Encounter” • Updated the logic definition for “Denominator 1” • Updated the logic definition for “Denominator 2” • Updated the logic definition for “Denominator 3”
Depression Remission or Response for Adolescents and Adults (DRR)	<ul style="list-style-type: none"> • Updated the logic definition for “Initial Population” • Updated the logic definition for “Denominator Exclusions” • Updated the logic definition for “Numerator 2” • Updated the logic definition for “Depression Follow Up Period” • Updated the logic definition for “Depression or dysthymia starts before or during first PHQ9 assessment” • Updated the logic definition for “Intake Period” • Updated the logic definition for “Last PHQ9 Assessment During Depression Follow Up Period”
Unhealthy Alcohol Use Screening and Follow-Up (ASF)	<ul style="list-style-type: none"> • Updated the logic definition for “Initial Population” • Updated the logic definition for “Screening Period” • Updated the logic definition for “Counseling or Other Follow-Up Care” • Updated the logic definition for “Positive Screen” • Updated the logic definition for “Denominator Exclusions”

Measure	Update
Adult Immunization Status (AIS)	<ul style="list-style-type: none"> • Deleted the logic definition for “Anaphylaxis Due to Haemophilus influenzae type b Vaccine” • Deleted the logic definition for “Second Herpes Zoster Recombinant Vaccine After Age 50” • Added the logic definition for “Adverse Reaction Caused by Influenza Vaccine” • Updated the logic definition for “Numerator 1” • Updated the logic definition for “Numerator 2” • Updated the logic definition for “2 Doses of Recombinant Zoster Vaccine” • Updated the logic definition for “Initial Population” • Updated the logic definition for “Denominator Exclusions” • Renamed the logic definition from First Herpes Zoster Recombinant Vaccine After Age 50” to “Herpes Zoster Recombinant Vaccine After Age 50”
Prenatal Immunization Status (PRS)	<ul style="list-style-type: none"> • Added the logic definition for “Continuously Enrolled 28 Days Before Delivery” • Updated the logic definition for “Initial Population” • Updated the logic definition for “Birth” • Updated the logic definition for “Numerator 2” • Updated the logic definition for “Numerator 3” • Updated the logic definition for “TD or TDAP Vaccine Contraindications” • Updated the logic definition for “Has Influenza Vaccine Adverse Reaction Before or During Measurement Period” • Updated the logic definition for “Has Influenza Vaccine 18 Months or Less Before End of Measurement Period and Delivery”

Volume 2 Header Language Updates

This document contains corrections, policy changes and clarifications to HEDIS 2019 *Volume 2, ECDS Technical Specifications*. NCQA has identified the appropriate page number, measure/guideline and head/subtitle for each item.

Page	Measure	Head/Subtitle	Update
495 (HEDIS 2019 Volume 2)	Depression Screening and Follow-Up for Adolescents and Adults (DSF)	Data Criteria (Element Level)	Under "Value Sets:" replace the 9th bullet with the following text: <ul style="list-style-type: none"> • "Medication, Dispensed: Antidepressant Medication (2.16.840.1.113883.3.464.1004.1503)" and • "Medication, Dispensed: Antidepressant Medication (Antidepressant Medications List from the MLD posted on the NCQA website: https://www.ncqa.org/hedis/measures/hedis-2019-ndc-license/)"
499 (HEDIS 2019 Volume 2)	Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (DMS)	Utilization of PHQ-9—Denominator 1	Replace the text in this section with the following text: The initial population, minus exclusions, with at least one <u>interactive outpatient encounter</u> during assessment period one, with a diagnosis of <u>major depression or dysthymia</u> .
		Utilization of PHQ-9—Denominator 2	Replace the text in this section with the following text: The initial population, minus exclusions, with at least one <u>interactive outpatient encounter</u> during assessment period two, with a diagnosis of <u>major depression or dysthymia</u> .
		Utilization of PHQ-9—Denominator 3	Replace the text in this section with the following text: The initial population, minus exclusions, with at least one <u>interactive outpatient encounter</u> during assessment period three, with a diagnosis of <u>major depression or dysthymia</u> .
502 (HEDIS 2019 Volume 2)	Depression Remission or Response for Adolescents and Adults (DRR)	Characteristics—Guidance, Allocation	Add the following text as the last two sentences in the Allocation paragraph: A gap in enrollment is allowed only in the measurement period. No gaps in enrollment are allowed from April 1 of the year prior to the measurement period through December 31 of the year prior to the measurement period.
29 (HEDIS 2019 Volume 2: Technical Update— Attachment A)	Adult Immunization Status (AIS)	Immunization Status: Influenza—Numerator 1	Replace the text in this section with the following text: Members in Denominator 1 who received an <u>influenza vaccine</u> on or between July 1 of the year prior to the measurement period and June 30 of the measurement period; or prior <u>influenza virus vaccine adverse reaction</u> any time during or before the measurement period.

Page	Measure	Head/Subtitle	Update
30 (HEDIS 2019 Volume 2: Technical Update— Attachment A)	Adult Immunization Status (AIS)	Data Criteria (Element Level)	Remove the following bullet from the “Direct Reference Codes:” list: <ul style="list-style-type: none"> • “Diagnosis: Anaphylaxis due to Haemophilus influenzae type b vaccine (SNOMEDCT Code 433621000124101)” Add the following as a new 4th bullet in the “Direct Reference Codes:” list: <ul style="list-style-type: none"> • “Diagnosis: Influenza Virus Vaccine Adverse Reaction (SNOMEDCT Code 420113004)”
33 (HEDIS 2019 Volume 2: Technical Update— Attachment B)	Prenatal Immunization Status (PRS)	Characteristics—Guidance, Allocation	Replace the text in this section with the following text: The member was continuously enrolled with a medical benefit and no gaps in enrollment during the participation period.
34 (HEDIS 2019 Volume 2: Technical Update— Attachment B)	Prenatal Immunization Status (PRS)	Immunization Status: Influenza—Numerator 1	Replace the text in this section with the following text: <u>Deliveries</u> where members received an <u>adult influenza vaccine</u> on or between July 1 of the year prior to the measurement period and the delivery date; or <u>deliveries</u> where members had an <u>influenza virus vaccine adverse reaction</u> any time during or before the measurement period.
		Immunization Status: Tdap—Numerator 2	Replace the second paragraph and the two bullets below the paragraph with the following text: <u>Deliveries</u> where member has a history of at least one of the following Td or Tdap contraindications that occurred any time before or during measurement period: <ul style="list-style-type: none"> • <u>Anaphylactic reaction to Tdap or Td vaccine or its components;</u> • <u>Encephalopathy due to Td or Tdap vaccination (post tetanus vaccination encephalitis, post diphtheria vaccination encephalitis, or post pertussis vaccination encephalitis).</u>